阿尔茨海默病大脑中的脂质组破坏:检测,病理机制和治疗含义
Sijia He1,2, Ziying Xu1, Xianlin Han3,4
1Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
Molecular neurodegeneration
|January 28, 2025
概括
脂质失调与阿尔茨海默病 (AD) 有关. 本综述探讨了AD诊断和治疗的脂质组学和脂质向策略,强调了脂质和AD病理之间的相互作用.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默氏病 (AD) 是一种主要的神经退行性疾病,有效治疗方法很少.
- 新兴研究表明,改变的脂质代谢在阿尔茨海默病的发病过程中起着重要作用.
- 具体的脂质谱及其在阿尔茨海默病中的机制在很大程度上仍然不清楚.
研究的目的:
- 审查脂管学在理解阿尔茨海默病中的作用.
- 突出用于AD诊断和治疗的脂质向方法.
- 总结当前关于脂质相互作用与AD特征的知识,如粉样蛋白β,,和神经炎症.
主要方法:
- 文献综述,重点关注脂管学技术及其在阿尔茨海默病研究中的应用.
- 对遗传和脂质物种数据的分析,将脑脂质失调与AD联系起来.
- 对脂质与AD主要病理特征之间的相互作用研究的审查.
主要成果:
- 脂质失调与AD在遗传和分子层面密切相关.
- 尽管面临当前的挑战,Lipidomics为AD研究提供先进的技术.
- 脂质与关键的AD病理有显著的相互作用,包括粉样β,tau和神经炎症.
结论:
- 脂管学对于阐明AD机制和开发新的治疗策略至关重要.
- 基于脂质的治疗方法有希望,但面临的障碍需要进一步研究.
- 利用脂管学可以为更有效的AD诊断和治疗铺平道路.
相关概念视频
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35


